ASCA IGG SACCHAROMYCES CEREVISIAE

The ASCA IgG (Saccharomyces cerevisiae) test measures IgG-class antibodies directed against Saccharomyces cerevisiae, a yeast antigen. Performed on serum, this serological assay helps detect an immune response that is frequently associated with inflammatory bowel disease (IBD), particularly Crohn’s disease; samples can be collected at home in Dubai by a licensed phlebotomist and processed in UAE‑accredited laboratories.

This test is used as an adjunct to clinical assessment, endoscopy and imaging to support differential diagnosis between Crohn’s disease and other gastrointestinal conditions, to monitor serologic trends, or to investigate unexplained chronic GI symptoms. Results should be interpreted alongside clinical findings and other investigations, as ASCA IgG is supportive but not solely diagnostic of IBD.

• ASCA IgG Antibody (Saccharomyces cerevisiae)
• ASCA IgG Titre (U/mL)
• Result Interpretation (Negative / Indeterminate / Positive)

• Persistent abdominal pain, diarrhea or weight loss suggesting chronic GI disease
• Suspected inflammatory bowel disease, especially when Crohn’s disease is considered
• To help differentiate IBD from irritable bowel syndrome (IBS)
• Monitoring serologic changes in patients with established IBD
• Unexplained extra‑intestinal features that may indicate autoimmune involvement

• Convenient Dubai home sample collection by licensed phlebotomists
• Supports differential diagnosis between Crohn’s disease and other GI disorders
• Quantitative titre provides a baseline for monitoring serologic trends
• Processed in UAE‑accredited laboratories with secure reporting to your clinician

• At‑home venous blood draw (serum sample, typically 2–5 mL)
• No fasting required for ASCA IgG serology
• Inform the phlebotomist/clinician about recent IVIG, blood transfusions, or immunosuppressive therapy
• Available across Dubai with collection by certified staff and lab processing in UAE‑accredited facilities